EMA401

• CAT Number: I001221
• CAS Number: 1316755-16-4
• Molecular Formula: C32H29NO5
• Molecular Weight: 507.58
• Purity: ≥95%
• Target: target: AT2R
• Solubility: DMSO ≥ 34mg/mL
• Storage: Store at -20°C

EMA401(CAT: I001221) is a highly selective antagonist of the angiotensin II type 2 receptor (AT2R). It is known to inhibit the augmented activation of p38 and p42/p44 mitogen-activated protein kinases (MAPK) induced by angiotensin II/AT2R signaling. By inhibiting this signaling pathway, EMA401 can reduce the hyperexcitability of dorsal root ganglion (DRG) neurons and prevent the sprouting of DRG neurons. These effects make EMA401 a potential therapeutic agent for conditions associated with neuronal hyperexcitability and neuropathic pain.

Reference

[1]. Anand U et al. Mechanisms underlying clinical efficacy of Angiotensin II type 2 receptor (AT2R) antagonist EMA401 in neuropathic pain: clinical tissue and in vitro studies. Mol Pain. 2015 Jun 26;11:38.

[2]. Rice AS et al. EMA401, an orally administered highly selective angiotensin II type 2 receptor antagonist, as a novel treatment for postherpetic neuralgia: a randomised, double-blind, placebo-controlled phase 2 clinical trial.
Lancet. 2014 May 10;383(9929):1637-47.

[3]. Rice AS et al. EMA401, an orally administered highly selective angiotensin II type 2 receptor antagonist, as a novel treatment for postherpetic neuralgia: a randomised, double-blind, placebo-controlled phase 2 clinical trial.
Lancet. 2014 May 10;383(9929):1637-47.